The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 9 of the 36 sources its claims cite were checked for support.
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Open accessAbstract
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut microbiome. In this open-label, single-center study (NCT03829111), 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk disease were randomized 2:1 to receive nivolumab and ipilimumab with or without daily oral CBM588, respectively. Stool metagenomic sequencing was performed at multiple timepoints. The primary endpoint to compare the relative abundance of Bifidobacterium spp. at baseline and at 12 weeks was not met, and no significant differences in Bifidobacterium spp. or Shannon index associated with the addition of CBM588 to nivolumab–ipilimumab were detected. Secondary endpoints included response rate, progression-free survival (PFS) and toxicity. PFS was significantly longer in patients receiving nivolumab–ipilimumab with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15, 95% confidence interval 0.05–0.47, P = 0.001). Although not statistically significant, the response rate was also higher in patients receiving CBM588 (58% versus 20%, P = 0.06). No significant difference in toxicity was observed between the study arms. The data suggest that CBM588 appears to enhance the clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab–ipilimumab. Larger studies are warranted to confirm this clinical observation and elucidate the mechanism of action and the effects on microbiome and immune compartments.
Overview
CoChat Summary
TL;DR
In a randomized phase 1 trial of 30 treatment-naive patients with metastatic renal cell carcinoma, adding the live bacterial product CBM588 to nivolumab–ipilimumab did not meet the primary microbiome endpoint of increasing Bifidobacterium spp. relative abundance at 12 weeks. However, CBM588 was associated with significantly longer progression-free survival and a numerically higher response rate without a significant toxicity difference.
Key findings
- The primary endpoint was not met: no significant change in relative abundance of Bifidobacterium spp. from baseline to week 12 with CBM588, and no significant differences in Bifidobacterium spp. or Shannon index between arms.
- Median PFS was 12.7 months with nivolumab–ipilimumab plus CBM588 versus 2.5 months without CBM588 (HR 0.15, 95% CI 0.05–0.47, P = 0.001).
- Objective response rate was 58% (11/19) with CBM588 versus 20% (2/10) without (P = 0.06); disease control was 79% versus 40%.
- Grade 3 or 4 treatment-attributable adverse events occurred in 52% of CBM588 patients versus 50% of control patients; no treatment-related deaths occurred.
Methods
- Open-label, single-center, randomized phase 1 trial (NCT03829111) in 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk IMDC disease; patients were randomized 2:1 to nivolumab–ipilimumab with or without daily oral CBM588 80 mg twice daily. One patient was deemed ineligible after treatment initiation, leaving 29 analyzed.
- Stool metagenomic sequencing was performed at baseline and 12 weeks; peripheral blood was collected for circulating cytokine and immune cell analyses. Primary endpoint: relative abundance of Bifidobacterium spp. at baseline and 12 weeks. Secondary endpoints included response rate, PFS, and toxicity.
- Analyses used Wilcoxon signed rank and Mann–Whitney U tests for microbiome/immune comparisons, Kaplan–Meier and log-rank tests for PFS/OS, and Fisher exact test for response rate.
Limitations
- The paper states limitations including small sample size, lack of a placebo control, absence of baseline tumor genomic profiling, limited long-term follow-up for overall survival, no planned patient-reported outcomes, inability to account for dietary intake variations, no exclusion of recent antibiotic therapy, and inability to rule out that species other than Bifidobacterium drove clinical outcomes.
- The paper also notes exploratory microbiome analyses were not adjusted for multiple comparisons and should be considered hypothesis generating.
- Evident from the text: this is a single-center phase 1 study with a 2:1 randomization and no stratification factors, limiting generalizability and power for clinical endpoints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Extended Data Fig. 2 Assessment of Shannon diversity index by treatment arm and treatment arm and response. Assessment of Shannon diversity index by treatment arm (a) and treatment arm and response (b). Gut microbiome diversity was assessed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non-responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Two-sided Mann-Whitney U test between nivolumab/ ipilimumab with CBM588 and nivolumab/ipilimumab. Two-sided Wilcoxon signed rank test between baseline and week 12. Shannon diversity index was calculated using the species-level abundance data (a,b). Source data](https://figures.cochat.ai/paper-figures/62142360a7b542b3b11801b44a5fbf4f/nivolumab-plus-ipilimumab-with-or-without-live-bacterial-supplementation-in-figure-6.jpg)
![Extended Data Fig. 3 Assessment of fungal microbiome characteristics at order level. Fungal microbiome analyses were performed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non- responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Taxa with a mean relative abundance less than 0.001 were summed as other. Source data](https://figures.cochat.ai/paper-figures/779c37bab04c466da65a80f23fede001/nivolumab-plus-ipilimumab-with-or-without-live-bacterial-supplementation-in-figure-7.jpg)



Verification
Claims the paper makes
5 Valid · 0 Not valid · 22 Not checked · 63 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in preclinical models, transplantation of fecal material enriched with Bifidobacterium spp. alone (even without CPIs) was sufficient to delay tumor growth4,5.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Main
What the sources say
- Partly supportedcites [4] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). sourceExperimental — accuracy not yet measured
Matson et al. (2018) do support the 'fecal transplant alone, without checkpoint blockade' half: in the FMT/Results section, reconstitution of GF mice with fecal material from responders gave 'slower baseline tumor growth' (two of three R cohorts, 'usually, but not always'), and responder feces were enriched in Bifidobacterium longum / Bifidobacteriaceae OTUs. However, the paper does not attribute that tumor delay to Bifidobacterium enrichment as such — it credits the association of Bifidobacteriaceae with improved immune-mediated tumor control in mouse models to earlier work (its reference 4, i.e. the preclinical anti–PD-L1 Bifidobacterium study), and states in Discussion that 'multiple specific bacteria may contribute,' with responder microbiota also rich in C. aerofaciens and E. faecium. The claim therefore overstates this source by isolating Bifidobacterium spp. as the sufficient element and by dropping the source's inconsistency hedge. (LLM, conf=0.75)
- Supportedcites [5] Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015). source
Our copy states that prophylactic transfer of JAX fecal material into TAC recipients 'was sufficient to delay tumor growth' and that JAX fecal transfer alone slowed established B16.SIY growth to the same degree as systemic αPD-L1, i.e. without checkpoint blockade (Results, Fig. 2A/D/E). Bifidobacterium is identified as the genus enriched in that material and uniquely associated with antitumor T cell responses (>400-fold increase in JAX-fed TAC mice; Fig. 3B-D), and oral Bifidobacterium alone likewise delayed tumor outgrowth in B16 parental and MB49 settings (fig. S4, B and C). All elements of the paraphrase — preclinical models, fecal/Bifidobacterium-enriched material, alone without CPIs, delayed tumor growth — are stated in the source. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer.”
- Also stated in: § Main · boosted
“Multiple groups have independently demonstrated a link between the gut microbiome and immunotherapy response in patients with cancer1–4.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Abstract
What the sources say
- Not checked yetcites [1] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). source
- Supportedcites [2] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). source
The paper's Discussion (final paragraph) states that its results indicate the gut microbiome may modulate responses to anti-PD-1 immunotherapy, and that the findings highlight therapeutic potential in 'patients receiving checkpoint blockade immunotherapy'; the Abstract and Introduction frame the cohort as metastatic melanoma patients on anti-PD-1 (n=112) with responder vs non-responder differences in gut diversity and Ruminococcaceae/Faecalibacterium abundance, plus fecal-transplant effects in germ-free mice. The citing sentence is hedged ('previous studies have suggested') at the same or lower confidence than the source, and the only qualifier it drops is the melanoma/anti-PD-1 specificity of this particular cohort, which the source itself generalises to checkpoint blockade in cancer patients. (LLM, conf=0.85)
- Not checked yetcites [3] Salgia, N. J. et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur. Urol. 78, 498–502 (2020). source
- Supportedcites [4] Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018). source
The Abstract of Matson et al. (2018) states a significant association between commensal microbial composition and clinical response to anti–PD-1 in metastatic melanoma patients, and concludes that 'the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients,' with fecal transfer from responders vs nonresponders recapitulating the phenotype in germ-free mice (p. passages 2, 5, 8). The citing sentence is a hedged, broad background statement ('previous studies have suggested...') and this paper is exactly such a study; its own framing generalizes beyond melanoma by noting two additional studies linking the microbiome to anti–PD-1 efficacy in different solid cancers (Routy et al., ref. 7) and preclinical anti–PD-L1 work (ref. 4). The only narrowing relative to the claim is that the human cohort here is metastatic melanoma on anti–PD-1, but the source itself asserts the point for 'human cancer patients,' so no qualifier is lost. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Main · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The live bacterial product CBM588 contains Clostridium butyricum, a butyrate-producing anaerobic spore-forming bacterium13–15.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Main
What the sources say
- Supportedcites [13] Hagihara, M. et al. Clostridium butyricum modulates the microbiome to protect intestinal barrier function in mice with antibiotic-induced dysbiosis. iScience 23, 100772 (2020). source
The Introduction identifies CBM 588 as Clostridium butyricum MIYAIRI 588, describes C. butyricum as an obligate anaerobe, and calls CBM 588 a butyrate-producing probiotic. The paper’s methods describe CBM 588 bacterial powder and measurement of C. butyricum spores in feces. Page numbers are not available in our copy. (LLM, conf=0.90)
- Partly supportedcites [14] Ariyoshi, T. et al. Clostridium butyricum MIYAIRI 588-induced protectin D1 has an anti-inflammatory effect on antibiotic-induced intestinal disorder. Front. Microbiol. 11, 587725 (2020). sourceExperimental — accuracy not yet measured
The Introduction identifies CBM 588 as a Clostridium butyricum strain and an obligate anaerobic bacterium, in the context of live-microorganism probiotics. The passages in our copy do not establish that it produces butyrate or forms spores, or explicitly describe a CBM588 product’s contents. (LLM, conf=0.87)
- Not checked yetcites [15] Isa, K. et al. Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo. Hum. Exp. Toxicol. 35, 818–832 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“previous in vivo studies assessing CBM588 have demonstrated upregulation of this metabolite27,28.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Discussion
What the sources say
- Could not verifycites [27] Louis, P. & Flint, H. J. Formation of propionate and butyrate by the human colonic microbiota. Environ. Microbiol. 19, 29–41 (2017). sourceExperimental — accuracy not yet measured
Our copy of Louis, Petra & Flint (2017) is a mechanistic review of propionate and butyrate pathways; the only mention of the bacterium behind CBM588 is Table 1 (Additional information), which lists Akkermansia muciniphila as genomically capable of propionate formation via the succinate pathway (+ (Suc)) among species detected in 586 faecal samples (Qin et al., 2010; Zhernakova et al., 2016). No passage reports or discusses in vivo administration studies of strain CBM588 or an upregulation/increase of propionate (or butyrate) concentrations resulting from such an intervention; searches for 'CBM588 / Akkermansia muciniphila in vivo propionate', 'gnotobiotic mice administration increased faecal propionate', and 'Akkermansia muciniphila succinate pathway' returned only the genomic-capability table, the succinate-pathway section (Pathways and bacterial groups contributing to propionate formation from carbohydrates), and reference-list entries. The in vivo evidence the citing sentence attributes therefore cannot be checked against this source. (LLM, conf=0.72)
- Not checked yetcites [28] Okamoto, T. et al. Preventive efficacy of butyrate enemas and oral administration of Clostridium butyricum M588 in dextran sodium sulfate-induced colitis in rats. J. Gastroenterol. 35, 341–346 (2000). source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“This hypothesis is based on previous preclinical work showing that oral Bifidobacterium spp. could improve the activity of CPIs in murine models5.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Discussion
What the sources say
- Supportedcites [5] Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015). source
The Abstract states that oral administration of Bifidobacterium alone improved tumor control to the same degree as PD-L1-specific antibody (checkpoint blockade) therapy and that combination treatment nearly abolished tumor outgrowth; the Results section (Fig. 3 discussion) describes oral gavage of a commercial Bifidobacterium spp. cocktail (B. breve, B. longum) given alone or with αPD-L1 to TAC mice bearing established tumors, with significantly improved tumor control in Bifidobacterium-treated mice. The paper also notes αPD-L1 therapy was significantly more efficacious in JAX mice than TAC mice. This matches the claim that oral Bifidobacterium spp. improves checkpoint-inhibitor activity in murine models. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
41 more claims
Create a free account to see all 90 claims and to verify the 27 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 15
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similar results were observed with the supplementation of a bifidogenic live bacterial product in renal carcinoma patients.39”
From Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Dizman et al. (2022) found that patients supplemented with CBM588 had significantly longer PFS.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Dizman et al., 2022
The cited source says what the claim attributes to it.
In the citing paper
“These microbes were also previously reported to be associated with better response to ICB immunotherapy2,3,38,39.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [39]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because MAdCAM-1 normally retains α 4 β 7 + type 17 T regulatory (Tr17) cells, its downregulation causes the exodus of such immunosuppressive cells from the gut toward extraintestinal tumors where they interfere with immunotherapy targeting the PD-1 immune checkpoint 8”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“However, interestingly, the studies did not reach their primary endpoint of increasing abundance of the probiotic bacteria.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [166]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Results > Assessment of circulating cytokines and immune cell populations
“Of 31 cytokines evaluated, only the level of monokine induced by interferon-γ (MIG, also known as CXCL9) was found to increase in both the nivolumab–ipilimumab and the nivolumab–ipilimumab plus CBM588 arms with time (P = 0.0078 and P < 0.0001, respectively).”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Discussion
“we saw significant increases in chemokines including CCL2 (MCP-1), CCL4 (MIP-1β), CXCL9 (MIG) and CXCL10 (IP-10) in patients receiving CBM588, but not in the control arm.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“In 12 evaluable subjects, two partial responses were observed, including one response in a patient with prior exposure to checkpoint inhibition. The response rate of 18% seen in their study”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Discussion
Reported 18 · recomputed 16.666667
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Arthralgia or myalgia | | | | 4 (22) | | |”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Results > Safety
Reported 22 · recomputed 21.052632
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Adrenal insufficiency | | | | 3 (19) | 1 (5) | |”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Results > Safety
Reported 19 · recomputed 15.789474
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Results > Assessment of circulating cytokines and immune cell populations
“Figure: Fig. 4 Changes in circulating cytokine levels from baseline to week 13 by treatment arm.”
§ Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial > Results > Assessment of circulating cytokines and immune cell populations
“We elected to use baseline and week 12 (±4 weeks) samples for this analysis because these are the typical timepoints used in first response assessment.”
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Improved metagenomic analysis with Kraken 2
Wood, D. E., Lu, J., & Langmead, B. (2019) · Genome Biology · doi:10.1186/s13059-019-1891-0 · Cited by 7,061
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Formation of propionate and butyrate by the human colonic microbiota
Louis, P., & Flint, H. J. (2017) · Environmental Microbiology · doi:10.1111/1462-2920.13589 · Cited by 3,028
Cited by
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
Metadata
- Authors
- Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., Hsu, J., Zengin, Z., Salgia, N., Salgia, S., Malhotra, J., Chawla, N., Chehrazi-Raffle, A., Muddasani, R., Gillece, J., Reining, L., Trent, J., Takahashi, M., Oka, K., Higashi, S., Kortylewski, M., Highlander, S. K., & Pal, S. K.
- Affiliations
- City Of Hope National Medical Center (US)
- Translational Genomics Research Institute (US)
- Miyarisan Pharmaceutical Co., Ltd. (Japan) (JP)
- Corresponding author
- Highlander, Sarah K.
- Pal, Sumanta K.
- ORCID
- Venue
- Nature Medicine
- Published
- 2022-02-28
- Volume
- 28
- Issue
- 4
- Pages
- 704-712
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9018425
- OpenAlex
- W4214706689
- Semantic Scholar
- 75ac6d52f29237478ff316edab1cf5339f3d0674
- Cited by
- 515
- References
- 48
- Citations by year
- 2026: 111 · 2025: 115 · 2024: 120 · 2023: 116 · 2022: 52
- FWCI
- 42.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Gateway for Cancer Research
- National Cancer Institute (P30CA033572)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- nivolumab, ipilimumab, metastatic renal cell carcinoma, gut microbiota, Bifidobacterium, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, response rate, stool metagenomics
- MeSH terms
- Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-022-01694-6
- The paper
- Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., Hsu, J., Zengin, Z., Salgia, N., Salgia, S., Malhotra, J., Chawla, N., Chehrazi-Raffle, A., Muddasani, R., Gillece, J., . . . Pal, S. K. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01694-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.